| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
22058 |
| Drug |
Tucatinib |
| Brand |
Tukysa® |
| Indication |
In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens. |
| Rapid review commissioned |
23/08/2022 |
| Rapid review completed |
20/09/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tucatinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
28/09/2022 |
| Pre-submission consultation with Applicant |
12/12/2023 |
| Full submission received from Applicant |
14/03/2024 |
| Preliminary review sent to Applicant |
06/12/2024 |
